As an effectual oral factor Xa inhibitor, Edoxaban is FDA approved as a novel anticoagulant therapy in the U.S. as an anticoagulant in several capacities: To reduce the risk with of both systemic embolism and stroke in patients afflicted with atrial fibrillation (AF), which is not related to heart valve problems. As a treatment for patients[…]
Edoxaban Is FDA Approved As Anticoagulant Therapy
Antithrombotic, Drug Research & Development API, FDA Approved 2015 Tags: anticoagulantWarfarin Mar 20, 2015
EU Approves Apixaban for DVT and PE Treatment and Prevention
Antithrombotic, Drug Research & Development API, EU Approved 2014 Tags: European Commission Aug 25, 2014
Bristol-Myers Squibb and Pfizer has announced that the European Commission has approved Apixaban (Eliquis) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. There is an estimated 600,000 people affected by DVT/PE each year in the U.S., and almost 100,000 of those people die[…]
FDA Approves Pivotal Cardiovascular Drug Vorapaxar
Antithrombotic, Cardiovascular Agent, Drug Research & Development API, FDA Approved 2014 Tags: Drug Administration May 15, 2014
On May 8, 2014 the U.S. Food and Drug Administration approved the formidable cardiovascular drug Vorapaxar. Known as the brand name Zontivity, which is marketed by Merck, this pivotal medication has proven to be outstanding in clinical trials. In three short years of study Vorapaxar demonstrated its ability to successfully reduce the rate of death[…]
Apixaban FDA Approval for Clotting in Post Orthopedic Surgery Patients
Antithrombotic, Drug Research & Development API Tags: Warfarin Mar 28, 2014
The FDA offered a nod of approval for the use of Apixaban when treating patients post orthopedic surgery. This recent endorsement of Bristol Myers’ brand name drug Eliquis {Apixaban} is timely and encouraging, with a little over one million orthopedic surgeries performed in the U.S. each year. The high risk of deep vein thrombosis or[…]
Lack of Available Alteplase Strikes a Chord Across the Medical Community
Antithrombotic, Drug Research & Development API Sep 25, 2013
As the only FDA approved agent for treating catheter occlusions, the current shortage of Alteplase has professionals in the acute and critical care arena reeling. The occurrence of catheter occlusion is a common, yet serious complication when dealing with patients who have central venous catheters. The occlusion typically occurs as a result of thrombosis, and[…]
75% of Men Not Receiving Appropriate Treatment for Erectile Dysfunction
Antithrombotic, Patent Expiration 2018 Tags: erectile dysfunctionGlaxoSmithKline Aug 13, 2013
At the 28th Annual EAU Congress, held in mid- March 2013 some startling statistic regarding men suffering from Erectile Dysfunction were revealed. Known also as ED, Erectile Dysfunction plagues almost 88 million men worldwide. Shocking numbers from a large clinical study of a subset of these patients, specifically a little over 6 million men, showed[…]
New Data Touts Value of Apixaban
Antithrombotic, Drug Research & Development API, FDA Approved 2012 Tags: anticoagulantatrial fibrillationWarfarin Jul 29, 2013
Exemplary news on July 1, 2013 revealed that Apixaban, known as the brand name Eliquis, had achieved its primary goal in studies. Marketed by both Pfizer and Bristol-Myers Squibb, Apixaban is an effective anticoagulant that has undergone strenuous testing, based on data from a recently released study coined AMPLIFY. Results from this comprehensive study were[…]
Clopidogrel Continues to Prove Its Safety and Efficacy
Antithrombotic, Blood Product, Drug Research & Development API, OTC and Compounding Product, Patent Expiration 2019 Tags: anticoagulantpercutaneous coronary interventionPlavix Jun 25, 2013
Clopidogrel Bisulfate, also known as the brand name anticoagulant medication Plavix, continues to impress with its safety profile. A study released at the end of March 2013 revealed that patients set to undergo percutaneous coronary intervention could successfully continue their regimen of Clopidogrel during this time. Caution was extended from the study investigators, which took[…]
Prasugrel Is Key to Successful Angioplasties
Antithrombotic, Blood Product, Drug Research & Development API, FDA Approved 2009, Patent Expiration 2017 Tags: percutaneous coronary interventionPlavix Nov 20, 2012
Known as the brand name Effient, Prasugrel was approved by the FDA in July of 2009 as a blood thinning drug. Designed to be used to reduce the risk of blood clots from forming in patients who undergo angioplasty, which is a common procedure to unblock a clogged coronary artery, Prasugrel was studied in close[…]
Eptifibatide Continues to be Successful as an Antiplatelet Agent
Antithrombotic, Blood Product, Bulk Active Ingredient, Patent Expiration 2014, Patent Expiration 2015, TEVA API Tags: percutaneous coronary intervention Aug 06, 2012
Eptifibatide, CAS# 188627-80-7, is an antiplatelet agent. Also offered from LGM Pharma as a TEVA API (TAPI) product for compounding purposes, eptifibatide is also known by the brand name Integrilin, which is marketed by Merck. With Merck’s patent for Integrilin due to expire on November 11, 2014, and an additional patent revision due to expire[…]
- 1
- 2
